U.S. regulators recommend suspension of Johnson & Johnson vaccine

Six women vaccinated with the vaccine developed blood clots

U.S. federal health authorities recommended Tuesday that Johnson & Johnson’s vaccine be suspended after six vaccinated women under the age of 50 were found to have rare thromboembolic complications.

Johnson & Johnson said it was delaying the rollout of its vaccine in Europe a week after regulators said they were investigating cases of blood clots in four people vaccinated with the vaccine in the United States.

Earlier this month, European regulators said they found a possible link between the AstraZeneca vaccine and a similarly rare blood clotting problem that has led to a small number of deaths.

The White House says the suspension of the single-unit J&J vaccine will not have a “significant” impact on vaccination plans. The administration expects to vaccinate 200 million people in the first 100 days of Joe Biden’s presidency.

As of April 12, more than 6.8 million doses of J&J vaccine and a total of more than 180 million doses of Moderna and Pfizer/BioNTech vaccines had been administered in the United States.

The Centers for Disease Control and Prevention (CDC) Advisory Committee will meet Wednesday to review the clotting cases, and the Food and Drug Administration (FDA) will review the findings, the two agencies said in a joint statement.

All six cases involved women between the ages of 18 and 48. They developed symptoms six to 13 days after the vaccination.

One woman died and another was hospitalized in critical condition, the New York Times reported, citing officials.

J&J says it is working closely with regulators and notes that no clear causal link has been found between the cases and the vaccine.

The company’s stock fell 2.6 percent in early New York trading

Leave a Reply

Your email address will not be published. Required fields are marked *